You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
遠大醫藥(00512.HK)2021年淨利約24.03億港元 同比增長約34.0%
格隆匯 03-17 22:58

格隆匯3月17日丨遠大醫藥(00512.HK)公吿,截至2021年12月31日止年度的收益約85.98億港元,同比增長約35.3%。公司擁有人應占年內溢利總額約24.03億港元,同比增長約34.0%。如撇除對Telix投資的公允價值變動收益及應占其他海外聯營公司業績,公司擁有人應占年內溢利總額約20.6億港元。截至2021年12月31日止年度的毛利率約61.0%(2020年:63.5%),同比下跌約2.5百分點。每股基本及攤薄盈利67.72港仙。

於2021年集團繼續堅持壁壘產品、品牌產品、原料製劑一體化的企業發展策略,不斷創造新的利潤增長點,並取得明顯經營成效。經過多年的不懈努力,集團的經營性利潤持續穏健增長,因此董事會建議派發末期股息每股11港仙。

現有業務持續穩定增長,與此同時集團大力投入產品研發和佈局,投入大量資源用於在臨牀前研究、臨牀試驗、上市註冊等工作,並與多間公司合作以取得不同產品的研發、生產及商業化等權利及用於加強進一步合作,合計投入超過港幣23.0億元。

面對中國醫療衞生體制改革不斷深化,集團順應市場發展及行業政策的變化,把握機遇,持續夯實自身科技創新實力,以患者需求為核心,以科技創新為原動力,針對尚未滿足的臨牀需求,加大對全球創新產品和先進技術的佈局,堅持"全球化運營佈局,雙循環經營發展"策略,着眼中國內外優質創新產品,深度佈局現有板塊,通過中國內外雙循環聯動發展,為全球患者提供更先進更多樣的治療方案,以提升集團的核心競爭力,併為股東及社會帶來更大回饋。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account